董事会 2023 年 8 月 10 日 创业慧康科技股份有限公司 关于选举产生第八届监事会职工代表监事的公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 创业慧康科技股份股份有限公司（以下简称"公司"）第七届监事会任期即 将届满，根据《中华人民共和国公司法》及《创业慧康科技股份有限公司章程》 等的有关规定，公司于 2023 年 8 月 9 日召开职工代表大会。经与会职工代表表 决，同意选举朱玲燕女士担任公司第八届监事会职工代表监事（简历详见附件）。 朱玲燕女士将与公司 2023 年第一次临时股东大会选举产生的 2 名非职工代 表监事共同组成公司第八届监事会，任期三年，自股东大会审议通过之日起计算。 特此公告。 创业慧康科技股份有限公司 证券代码：300451 证券简称：创业慧康 公告编号：2023-042 附件： 朱玲燕女士，1982 年出生，中国国籍，大专学历，中级会计师，历任浙江 建达科技股份有限公司财务部出纳，成本会计，收入会计。现任杭州慧康物联网 科技有限公司财务部经理。 截至本公告日，朱玲燕女士未持有公司股票，与持有公司 5%以上股份的股 东、实际控 ...

是 □ 否 创业慧康科技股份有限公司 独立董事候选人声明 声明人凌云作为创业慧康科技股份有限公司第八届董事会独立董事候选人， 现公开声明和保证，本人与该公司之间不存在任何影响本人独立性的关系，且 符合相关法律、行政法规、部门规章、规范性文件和深圳证券交易所业务规则 对独立董事候选人任职资格及独立性的要求，具体声明并承诺如下事项： 一、本人已经通过创业慧康科技股份有限公司第七届董事会提名委员会资 格审查（如适用），提名人与本人不存在利害关系或者可能妨碍本人独立履职的 其他关系。 六、本人担任独立董事不会违反《中华人民共和国公务员法》的相关规定。 是 □ 否 七、本人担任独立董事不会违反中共中央纪委《关于规范中管干部辞去公职 或者退（离）休后担任上市公司、基金管理公司独立董事、独立监事的通知》的 相关规定。 二、本人不存在《中华人民共和国公司法》第一百四十六条等规定不得担任 公司董事的情形。 是 □ 否 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易所 自律监管规则规定的独立董事任职资格和条件。 是 □ 否 四、本人符合该公司章程规定的独立董事任职条件。 是 □ 否 五、本人已经参加培训且培训时 ...

证券代码：300451 证券简称：创业慧康 公告编号：2023-043 创业慧康科技股份有限公司 关于召开2023年第一次临时股东大会的通知 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 创业慧康科技股份有限公司（以下简称"公司"）于 2023 年 8 月 9 日召开 了第七届董事会第二十九次会议，会议决定于 2023 年 8 月 25 日召开 2023 年第 一次临时股东大会。本次股东大会采用现场投票、网络投票相结合的方式进行， 现将本次会议的有关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2023 年第一次临时股东大会 2、股东大会的召集人：公司第七届董事会 3、会议召开的合法、合规性 2023 年第一次临时股东大会会议的召集、召开符合有关法律、行政法规、部 门规章、规范性文件和公司章程的相关规定。 4、会议召开时间： （1）现场会议召开时间：2023 年 8 月 25 日（星期五）14:30 （2）网络投票时间：2023 年 8 月 25 日，其中： ①通过深交所交易系统进行网络投票的时间为 2023 年 8 月 25 日上午 9:15-9: ...

创业慧康科技股份有限公司 独立董事关于第七届董事会第二十九次会议 相关事项的独立意见 我们作为创业慧康科技股份有限公司（以下简称"公司"）的独立董事，根 据《公司法》《证券法》《上市公司独立董事规则》《深圳证券交易所上市公司 自律监管指引第 2 号——创业板上市公司规范运作》及公司《公司章程》《独立 董事制度》等相关法律法规、规章制度的规定，基于独立判断立场，本着实事求 是的原则，对公司第七届董事会第二十九次会议相关事项进行了认真的审议，并 发表以下独立意见： 一、关于公司董事会换届选举暨提名第八届董事会非独立董事候选人的独 立意见 1、本次公司董事会换届选举暨提名公司第八届董事会非独立董事候选人的 程序符合有关法律、法规和《公司章程》的规定。 2、经核查公司第八届董事会非独立董事候选人的简历等相关资料，未发现 有《公司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公 司规范运作》《公司章程》《董事会议事规则》规定不得担任董事的情形，不存 在被中国证券监督管理委员会确定为市场禁入者并且禁入尚未解除的情况，也未 曾受到中国证券监督管理委员会和深圳证券交易所的任何处罚和惩戒。公司第八 届董事会非 ...

Financial Performance - The company's operating revenue for the first quarter was RMB 348,436,396.10, a decrease of 24.74% compared to the previous year[9]. - Net profit attributable to shareholders was RMB 10,383,267.51, down 88.74% year-on-year[9]. - The company's net profit for Q1 2023 was CNY 10,089,131.60, a significant decrease of 89.00% compared to CNY 91,810,723.47 in the same period last year[40]. - The total revenue for the first quarter was CNY 348,436,396.10, a decrease of 24.7% compared to CNY 462,990,891.86 in the previous period[49]. - The total operating costs for the first quarter were CNY 324,567,187.37, down from CNY 343,652,104.79 in the previous period[49]. - The total comprehensive income attributable to the parent company was CNY 10,383,267.51, compared to CNY 92,246,842.09 in the previous period, indicating a significant decrease[51]. - Basic and diluted earnings per share both stood at CNY 0.01, down from CNY 0.06 in the prior period[51]. Cash Flow and Assets - The net cash flow from operating activities was RMB -186,610,096.05, showing an improvement of 10.89% compared to the previous year[9]. - Cash inflows from operating activities totaled CNY 259,880,225.83, an increase from CNY 246,729,050.01 in the previous period[51]. - Cash outflows from operating activities were CNY 446,490,321.88, slightly decreased from CNY 456,132,775.25 in the prior period[51]. - The ending balance of cash and cash equivalents was CNY 1,083,209,704.77, down from CNY 1,478,027,707.71 at the beginning of the year[54]. - The company's cash flow from the disposal of fixed assets, intangible assets, and other long-term assets increased by 612.79% year-on-year[30]. - Cash received from investment activities decreased by 43.69% year-on-year, attributed to fewer proceeds from the disposal of equity in joint ventures[30]. - The company's accounts receivable financing decreased by 69.97% compared to the beginning of the year, mainly due to the maturity of bank acceptance bills[29]. - Accounts receivable increased to CNY 1,502,466,642.37 from CNY 1,390,763,883.83 at the beginning of the year[54]. - Other receivables rose to CNY 46,632,360.69 from CNY 43,901,512.53 at the beginning of the year[54]. Investments and Expenditures - Investment income increased by 113.33% year-on-year, primarily due to losses from the disposal of equity in joint ventures in the previous year[30]. - Financial expenses decreased by CNY 3,944,500.00, mainly due to reduced borrowing fees and interest expenses[30]. - Research and development expenses increased to CNY 60,757,083.52, compared to CNY 48,849,670.94 in the previous period, reflecting a growth of 24.3%[49]. - The company achieved a 156.11% increase in development expenditures compared to the beginning of the year, primarily due to increased capitalization of R&D projects[12]. - The company is committed to maintaining its R&D investment to drive future growth and innovation[49]. Strategic Developments - The company secured 7 large orders in the healthcare information technology sector, exceeding the same period last year[5]. - The company has formed a strategic partnership with Zhejiang University Computer Innovation Technology Research Institute to enhance AI model development in healthcare[5]. - The company showcased its five major product segments at the 2023 CHITEC, receiving recognition for its "Next-Generation Grassroots Health Cloud" project[5]. - The company received multiple honors, including "Zhejiang Province Technology Small Giant Enterprise" and "Zhejiang Province Invisible Champion Enterprise" during the reporting period[5]. Liabilities and Equity - The company's total liabilities amounted to CNY 925,528,000.94, a decrease from CNY 1,181,763,740.80 in the previous period[49]. - The total equity attributable to shareholders of the parent company was CNY 4,618,302,252.69, up from CNY 4,593,661,374.82 in the previous period[49]. - The number of common shareholders at the end of the reporting period was 29,208, with the largest shareholder holding 14.23%[44]. - The company has a total of 220,519,182 shares held by its largest shareholder, Ge Hang, with 165,389,386 shares under lock-up[45]. Taxation and Impairments - The company's income tax expense decreased by 93.29% year-on-year, primarily due to a reduction in total profit[30]. - The company reported a tax and additional charges of CNY 1,877,061.06, significantly lower than CNY 4,844,066.20 in the previous period[49]. - The company's credit impairment losses increased by 35.72% year-on-year, mainly due to an increase in bad debt provisions[30]. - The company reported a decrease in other investment-related cash receipts by 87.98% year-on-year, mainly due to a reduction in purchased financial products[30].

证券代码：300451 证券简称：创业慧康 创业慧康科技股份有限公司投资者关系活动记录表 2023-003 投资者关系活动 类别 ☐特定对象调研 ☐分析师会议 ☐媒体采访 业绩说明会 ☐新闻发布会 ☐路演活动 ☐现场参观 ☐其他（请文字说明其他活动内容） 参与单位名称 及人员姓名 线上参与公司2022年度业绩网上说明会的全体投资者 时间 2023年04月26日 15:00-17:00 地点 公司通过"价值在线"（https://www.ir-online.cn/）采用网络远程的 方式召开业绩说明会 上市公司接待人 员姓名 董事长兼总经理 张吕峥先生 董事兼董事会秘书 胡燕女士 财务负责人 郁燕萍女士 独立董事 谭青女士 投资者关系活 动主要内容介 绍 公司就投资者在本次说明会中提出的问题进行了回复： 1、今天的业绩说明会开始了没？ 您好，今天的业绩说明会将于下午3点开始，谢谢。 2、公司在技术服务上主要有哪些服务，是否可以展开说 明？目前合作客户有哪些？ 您好，公司成立以来始终秉承"创造智慧医卫，服务健康 事业"的企业宗旨，专注于医疗卫生健康信息化的建设、研发 及服务创新，依托"慧康云战略"，构建横向业务发展 ...

Market Position and Competition - The company has maintained a leading position in the healthcare information technology sector, establishing a solid market share and brand image[6]. - The company faces intensified competition due to increasing demand for IT services and the entry of new competitors, which may pose risks to its market position[6]. - The company aims to strengthen its market position by expanding its product line and health service ecosystem, enhancing profitability in response to national policy adjustments and macroeconomic changes[45]. - The company is positioned to benefit from increasing industry orders and the trend of market consolidation towards leading firms[121]. Research and Development - The company plans to increase investment in R&D, human resources, and market research to enhance product development and maintain technological advantages[4]. - The company emphasizes the importance of collaboration with renowned universities and research institutions to develop new products and maintain a strong technical foundation[4]. - The company has developed over 300 proprietary products and holds more than 30 invention patents and around 900 software copyrights, demonstrating strong R&D capabilities[69]. - The company’s R&D department follows the CMMI5 software maturity development process, ensuring high-quality control and product testing throughout the development cycle[135]. Financial Performance - The company’s operating revenue for 2022 was ¥1,527,138,670.24, a decrease of 19.58% compared to ¥1,898,976,983.54 in 2021[112]. - The net profit attributable to shareholders for 2022 was ¥42,637,972.84, down 89.68% from ¥413,039,235.38 in 2021[112]. - The net profit after deducting non-recurring gains and losses was ¥46,863,629.56, a decline of 87.90% from ¥387,332,119.99 in 2021[112]. - The basic earnings per share for 2022 was ¥0.03, down 88.89% from ¥0.27 in 2021[112]. Product and Service Development - The company is expanding its business into areas such as smart healthcare, internet medical services, and health big data, which requires effective implementation strategies[16]. - The company has launched a comprehensive IoT access solution for hospitals, addressing the challenges of managing diverse protocols and devices, thereby reducing maintenance difficulties and costs[59]. - The company has developed a smart IoT support platform, creating a service system that includes convenience services, clinical applications, operational management, and health services[54]. - The company is focusing on integrating new technologies such as IoT and big data into hospital systems to improve patient-centered care models[60]. Strategic Initiatives - The company is actively pursuing a "Cloud Strategy" to enhance customer satisfaction and deliver on existing orders, focusing on a patient-centered healthcare system[35]. - The company is committed to enhancing the operational efficiency of healthcare institutions through cloud-based maintenance services and intelligent terminal integration[59]. - The company is committed to becoming a leader in the "Healthy China" initiative, aligning its strategies with national health policies and technological advancements[109]. - The company is exploring innovative applications in traditional Chinese medicine through an internet cloud clinic project, providing online appointment and consultation services[88]. Client and Market Engagement - The company’s main clients are public hospitals and health management departments, with project acceptance and payment concentrated in the second half of the year, particularly in Q4[7]. - The company has established 11 regional marketing service centers and 15 provincial marketing service centers, ensuring timely communication and localized services for clients across 30 provinces[70]. - The company has implemented nearly 20,000 healthcare information projects, serving over 7,000 industry users and covering more than 370 districts nationwide, accumulating approximately 300 million resident health records[68]. - The company has established partnerships with 15 internet hospitals in Zhongshan, including 4 top-tier hospitals, to provide convenient online medical services[179]. Technology Integration and Innovation - The company is developing a comprehensive medical IoT application framework, supporting 5G network applications and various IoT transmission protocols[178]. - The company has successfully launched the first fully cloud-based hospital information system solution for a major medical group in Zhejiang, supporting an average daily outpatient volume of nearly 20,000 patients and over 4,000 total beds[157]. - The company has integrated its intelligent medical services into various internet hospitals and health city applications, providing smart consultation and guidance services[167]. - The company is actively involved in building data service platforms to improve real-time monitoring and efficiency of healthcare services[104]. Regulatory and Policy Environment - The company acknowledges the risk of talent loss and rising human resource costs due to intensified market competition, which could impact its operational performance[19]. - The company’s future business operations may face uncertainties due to potential changes in national policy and macroeconomic conditions[21]. - The government emphasizes the development of smart healthcare and encourages the integration of emerging technologies like AI, big data, and 5G into medical services[127]. - The integration of health data and the establishment of a comprehensive health information system are key tasks outlined for the next five years[127].

证券代码：300451 证券简称：创业慧康 公告编号：2023-017 创业慧康科技股份有限公司 关于举行 2022 年度业绩网上说明会的公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 创业慧康科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 15 日在 巨潮资讯网披露了《2022 年年度报告》及《2022 年年度报告摘要》。为便于广 大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司定于 2023 年 4 月 26 日（星期三）15:00-17:00 在"价值在线"（www.ir-online.cn）举办 2022 年度业绩说明会，与投资者进行沟通和交流，广泛听取投资者的意见和建议。 一、说明会召开的时间、地点和方式 投 资 者 可 于 2023 年 4 月 26 日 （ 星 期 三 ） 15:00-17:00 通过网址 https://eseb.cn/13GibIYbQas 或使用微信扫一扫以下小程序码即可进入参与互动 交流。投资者可于 2023 年 4 月 26 日前进行访问，打开互动交流进行会前提问， 公司将通过本次业绩说明会 ...